PHASE II TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH LENALIDOMIDE AND BORTEZOMIB

被引：0
|
作者：
Mian, M.
Pescosta, N. [1 ]
Luminari, S. [2 ]
Badiali, S. [2 ]
Marcheselli, L. [2 ]
Patriarca, F. [3 ]
Zambello, R. [4 ]
Mondello, P. [5 ]
Pascarella, A. [6 ]
Pitini, V. [5 ]
Cortelazzo, S. [7 ]
机构：
[1] Hosp Bolzano, Bolzano, Italy
[2] Univ Modena & Reggio Emilia, Dept Hematol & Oncol, Modena, Italy
[3] Azienda Osped Univ, Udine, Italy
[4] Univ Padua, Sch Med, Padua, Italy
[5] Univ Messina, Messina, Italy
[6] Osped Angelo, Venice, Mestre, Italy
[7] Humanitas Gavazzeni Canc Ctr, Bergamo, Italy
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1648
引用
收藏
页码：637 / 637
页数：1
相关论文
共 50 条
  • [21] Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial
    Kumar, Sudhir
    Sharma, Atul
    Malik, Prabhat Singh
    Gogia, Ajay
    Pathak, Neha
    Sahoo, Ranjit Kumar
    Gupta, Ritu
    Prasad, Chandra Prakash
    Kumar, Lalit
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (02) : 288 - 297
  • [22] Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma
    Fenk, Roland
    Michael, Mark
    Zohren, Fabian
    Graef, Thorsten
    Czibere, Akos
    Bruns, Ingmar
    Neumann, Frank
    Fenk, Barbara
    Haas, Rainer
    Kobbe, Guido
    LEUKEMIA & LYMPHOMA, 2007, 48 (12) : 2345 - 2351
  • [23] BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Cerchione, C.
    Pareto, A. E.
    Zacheo, I.
    Di Perna, M.
    Nappi, D.
    Peluso, I.
    Ferrara, K.
    Pane, F.
    Catalano, L.
    HAEMATOLOGICA, 2018, 103 : S116 - S117
  • [24] Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma
    Schmielau, J
    Teschendorf, C
    König, M
    Schmiegel, W
    Graeven, U
    LEUKEMIA & LYMPHOMA, 2005, 46 (04) : 567 - 569
  • [25] EFFICACY AND SAFETY OF BORTEZOMIB PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Sanchez, R. Garcia
    Saldana, R.
    Caparros, I.
    Gallardo, A.
    Garcia-Delgado, R.
    Rosell, A.
    Campos, A.
    de Llano, M. P. Queipo
    Perez, I.
    Moreno, M. J.
    Del Castillo, S.
    De la Torre, S.
    Ramirez, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 500 - 500
  • [26] IMPACT OF NUMBER OF PREVIOUS TREATMENT LINES AND PRE-TREATMENT WITH BORTEZOMIB OR LENALIDOMIDE ON EFFICACY OF BORTEZOMIB-BENDAMUSTINE-DEXAMETHASONE (BBD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)
    Ludwig, H.
    Kasparu, H.
    Leitgeb, C.
    Greil, R.
    Rauch, E.
    Linkesch, W.
    Zojer, N.
    Pour, L.
    Fillitz, M.
    Adam, Z.
    ANNALS OF ONCOLOGY, 2012, 23 : 348 - 349
  • [27] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
    Paludo, Jonas
    Mikhael, Joseph R.
    LaPlant, Betsy R.
    Halvorson, Alese E.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis K.
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Go, Ronald S.
    Lin, Yi
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Chanan-Khan, Asher A.
    Ailawadhi, Sikander
    Stewart, A. Keith
    Reeder, Craig B.
    Richardson, Paul G.
    Rajkumar, S. Vincent
    Lacy, Martha Q.
    BLOOD, 2017, 130 (10) : 1198 - 1204
  • [28] BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) COMBINATION FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF A PHASE II STUDY
    Offidani, M.
    Corvatta, L.
    Caraffa, P.
    Liberati, A. M.
    Alesiani, F.
    Brunori, M.
    di Toritto, T. Caravita
    Gentili, S.
    Attolico, I.
    Mele, A.
    Pulini, S.
    Ballanti, S.
    Galimberti, S.
    Gozzetti, A.
    Coppetelli, U.
    Ledda, A.
    Leoni, P.
    HAEMATOLOGICA, 2012, 97 : 353 - 353
  • [29] Vorinostat, Bortezomib, Cyclophosphomide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
    Gleason, Charise
    Kaufman, Jonathan L.
    Nooka, Ajay K.
    Valla, Kelly
    Heffner, Leonard T.
    Bisht, Aditya Singh
    Manubolu, Sanjay
    Watson, Melanie
    Boise, Lawrence H.
    Lonial, Sagar
    BLOOD, 2014, 124 (21)
  • [30] Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
    Dimopoulos, M. A.
    Swern, A. S.
    Li, J. S.
    Hussein, M.
    Weiss, L.
    Nagarwala, Y.
    Baz, R.
    BLOOD CANCER JOURNAL, 2014, 4 : e257 - e257
12345